危重儿童使用神经肌肉阻滞剂:倾向评分加权分析评估死亡风险
该研究基于意大利17个PICU的国家注册数据库,纳入2010年1月至2017年10月接受机械通气的18岁以下患儿3823例,比较持续输注神经肌肉阻滞剂与否的住院死亡风险。使用倾向评分加权Cox回归分析,神经肌肉阻滞剂组死亡率21%,非暴露组11%(p<0.001)。加权分析显示神经肌肉阻滞剂使用是住院死亡的显著预测因子(未调整HR 1.7,95%CI 1.3-2.2;调整后HR 1.6,95%CI 1.2-2.1),且与更长的机械通气时间和PICU停留相关。
要点
- 在机械通气危重患儿中,持续输注神经肌肉阻滞剂与住院死亡风险独立相关(调整后HR 1.6,95%CI 1.2-2.1)。
- 神经肌肉阻滞剂暴露组住院死亡率为21%,非暴露组为11%(p<0.001,加权logistic回归)。
- 神经肌肉阻滞剂暴露组机械通气时间和PICU停留时间均显著更长(均p<0.001,加权logistic回归)。
- 该研究为观察性设计,不能确立因果关系,需前瞻性研究验证。
适用人群与场景
- 意大利17个PICU中2010年1月至2017年10月收治的18岁以下、接受机械通气并持续输注神经肌肉阻滞剂的患儿(共3823例纳入分析)。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:多中心、基于注册数据库的观察性、两队列比较回顾性研究,使用前瞻性收集的意大利全国网络注册数据,共17个PICU。
- 样本量:研究期间PICU共收治23227例,最终纳入3823例接受机械通气的患儿。
- 干预与对照:持续输注神经肌肉阻滞剂 vs 未持续输注神经肌肉阻滞剂,无其他干预。
- 主要终点:住院死亡率,神经肌肉阻滞剂组21% vs 非暴露组11%(p<0.001,加权logistic回归)。
- 关键次要终点:神经肌肉阻滞剂组机械通气时间和PICU停留时间均显著更长(均p<0.001,加权logistic回归)。
- 效应量:加权Cox回归分析显示神经肌肉阻滞剂使用是住院死亡的显著预测因子,未调整HR 1.7(95%CI 1.3-2.2),调整后HR 1.6(95%CI 1.2-2.1)。
- 不良事件:原文未提及。
证据类型、等级与局限
- 证据类型:多中心回顾性观察性队列研究(基于注册数据库),非RCT。
- 证据等级或推荐强度:原文未提及。
- 局限:回顾性设计、观察性研究不能确立因果关系;使用倾向评分加权控制选择偏倚,但仍可能存在未测量混杂;原文未提及样本量计算、单中心或开放标签等具体局限。
对床旁实践的改变
- 该研究提示在危重机械通气患儿中,持续输注神经肌肉阻滞剂与住院死亡风险升高独立相关(调整后HR 1.6,95%CI 1.2-2.1),临床决策时应权衡获益与潜在风险。
- 该研究为观察性设计,不能证明因果关系,适用人群为18岁以下机械通气患儿,不适用于非机械通气患儿;常见陷阱是将关联误认为因果。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: We aim to describe the use of continuous infusion of neuromuscular blocking agents in mechanically ventilated critically ill children and to test its association with in-hospital mortality.
DESIGN: Multicenter, registry-based, observational, two-cohort-comparison retrospective study using prospectively collected data from a web-based national registry.
SETTING: Seventeen PICUs in Italy.
PATIENTS: We included children less than 18 years who received mechanical ventilation and a neuromuscular blocking agent infusion from January 2010 to October 2017. A propensity score-weighted Cox regression analysis was used to assess the relationship between the use of neuromuscular blocking agents and in-hospital mortality.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Of the 23,227 patients admitted to the PICUs during the study period, 3,823 patients were included. Patients who received a continuous infusion of neuromuscular blocking agent were more likely to be younger (p < 0.001), ex-premature (p < 0.001), and presenting with less chronic respiratory insufficiency requiring home mechanical ventilation (p < 0.001). Reasons for mechanical ventilation significantly differed between patients who received a continuous infusion of neuromuscular blocking agent and patients who did not receive a continuous infusion of neuromuscular blocking agent, with a higher frequency of respiratory and cardiac diagnosis among patients who received neuromuscular blocking agents compared with other diagnoses (all p < 0.001). The covariates were well balanced in the propensity-weighted cohort. The mortality rate significantly differed among the two cohorts (patients who received a continuous infusion of neuromuscular blocking agent 21% vs patients who did not receive a continuous infusion of neuromuscular blocking agent 11%; p < 0.001 by weighted logistic regression). Patients who received a continuous infusion of neuromuscular blocking agent experienced longer mechanical ventilation and PICU stay (both p < 0.001 by weighted logistic regression). A weighted Cox regression analysis found the use of neuromuscular blocking agents to be a significant predictor of in-hospital mortality both in the unadjusted analysis (hazard ratio, 1.7; 95% CI, 1.3-2.2) and in the adjusted one (hazard ratio, 1.6; 95% CI, 1.2-2.1).
CONCLUSIONS: Thirteen percent of mechanically ventilated children in PICUs received neuromuscular blocking agents. When adjusting for selection bias with a propensity score approach, the use of neuromuscular blocking agent was found to be a significant predictor of in-hospital mortality.
参考来源
- Daverio M, Sperotto F, Stefani C, et al. Neuromuscular Blocker Use in Critically Ill Children: Assessing Mortality Risk by Propensity Score-Weighted Analysis. Crit Care Med. 2022. PMID: 34582423. doi:10.1097/CCM.0000000000005334
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。